melatonin has been researched along with Drug Withdrawal Symptoms in 35 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "We assessed if prolonged-release melatonin can facilitate withdrawal of long-term benzodiazepine usage in patients with schizophrenia or bipolar disorder." | 9.22 | Prolonged-release melatonin versus placebo for benzodiazepine discontinuation in patients with schizophrenia or bipolar disorder: A randomised, placebo-controlled, blinded trial. ( Baandrup, L; Glenthoj, BY; Gluud, C; Lindschou, J; Winkel, P, 2016) |
| "Five patients with rapid-cycling DSM-III-R bipolar disorder were treated with melatonin 10 mg q." | 9.08 | Effects of exogenous melatonin administration and withdrawal in five patients with rapid-cycling bipolar disorder. ( Feldman-Naim, S; Leibenluft, E; Rosenthal, NE; Turner, EH; Wehr, TA, 1997) |
| " Reduced benzodiazepine dosage at the 24-week follow-up was associated with a significantly decreased proportion of stage 2 sleep." | 6.82 | Objective and subjective sleep quality: Melatonin versus placebo add-on treatment in patients with schizophrenia or bipolar disorder withdrawing from long-term benzodiazepine use. ( Baandrup, L; Glenthøj, BY; Jennum, PJ, 2016) |
| "We assessed if prolonged-release melatonin can facilitate withdrawal of long-term benzodiazepine usage in patients with schizophrenia or bipolar disorder." | 5.22 | Prolonged-release melatonin versus placebo for benzodiazepine discontinuation in patients with schizophrenia or bipolar disorder: A randomised, placebo-controlled, blinded trial. ( Baandrup, L; Glenthoj, BY; Gluud, C; Lindschou, J; Winkel, P, 2016) |
| "Five patients with rapid-cycling DSM-III-R bipolar disorder were treated with melatonin 10 mg q." | 5.08 | Effects of exogenous melatonin administration and withdrawal in five patients with rapid-cycling bipolar disorder. ( Feldman-Naim, S; Leibenluft, E; Rosenthal, NE; Turner, EH; Wehr, TA, 1997) |
| " Only few controlled studies have characterized the effect of discontinuation of their chronic use on sleep and quality of life." | 2.90 | Withdrawal from long-term use of zopiclone, zolpidem and temazepam may improve perceived sleep and quality of life in older adults with primary insomnia. ( Kivelä, SL; Lähteenmäki, R; Neuvonen, PJ; Partinen, M; Puustinen, J; Räihä, I; Vahlberg, T, 2019) |
| " Reduced benzodiazepine dosage at the 24-week follow-up was associated with a significantly decreased proportion of stage 2 sleep." | 2.82 | Objective and subjective sleep quality: Melatonin versus placebo add-on treatment in patients with schizophrenia or bipolar disorder withdrawing from long-term benzodiazepine use. ( Baandrup, L; Glenthøj, BY; Jennum, PJ, 2016) |
| " Participants were randomized to add-on treatment with prolonged-release melatonin (2 mg) or matching placebo, and usual benzodiazepine dosage was gradually tapered." | 2.82 | Circadian rest-activity rhythms during benzodiazepine tapering covered by melatonin versus placebo add-on: data derived from a randomized clinical trial. ( Baandrup, L; Fasmer, OB; Glenthøj, BY; Jennum, PJ, 2016) |
| "Melatonin treatment for two months significantly improved sleep quality scores measured by the NHSMI test (1." | 2.74 | Effect of melatonin administration on sleep, behavioral disorders and hypnotic drug discontinuation in the elderly: a randomized, double-blind, placebo-controlled study. ( Aramburu, O; Garzón, C; Guerrero, JM; Guzmán, T, 2009) |
| "Patients with DSM-IV-TR major depressive disorder who responded to an 8- or 10-week course of agomelatine 25- or 50-mg daily treatment were randomly assigned to receive continuation treatment with agomelatine (n=165) or placebo (n=174) during a 24-week, randomized, double-blind treatment period." | 2.74 | Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial. ( Emsley, R; Goodwin, GM; Rembry, S; Rouillon, F, 2009) |
| "Methadone maintenance treatment clinic." | 2.73 | Melatonin for perceived sleep disturbances associated with benzodiazepine withdrawal among patients in methadone maintenance treatment: a double-blind randomized clinical trial. ( Adelson, M; Bar-Hamburger, R; Hetzroni, T; Peles, E; Schreiber, S, 2007) |
| "Rebound insomnia and withdrawal effects following discontinuation were also evaluated." | 2.73 | Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects. ( Laudon, M; Lemoine, P; Nir, T; Zisapel, N, 2007) |
| "Melatonin (MLT) has been prescribed as a treatment for BZD/HYP detoxification." | 2.66 | Melatonin and melatonin agonists as treatments for benzodiazepines and hypnotics withdrawal in patients with primary insomnia. A systematic review. ( Abreu-Gonzalez, P; Fernandez-Lopez, L; Morera-Fumero, AL, 2020) |
| " After long-term use it is often difficult to discontinue benzodiazepines due to psychological and physiological dependence." | 2.58 | Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users. ( Baandrup, L; Ebdrup, BH; Glenthøj, BY; Gluud, C; Lindschou, J; Rasmussen, JØ, 2018) |
| "Treatment with melatonin during withdrawal restored METH-induced mitochondria and synaptic impairments." | 1.91 | Proteomic Analysis Reveals the Neurotoxic Effects of Chronic Methamphetamine Self-Administration-Induced Cognitive Impairments and the Role of Melatonin-Enhanced Restorative Process during Methamphetamine Withdrawal. ( Chetsawang, B; Cornish, JL; Na Nakorn, P; Ngampramuan, S; Panmanee, J; Pannengpetch, S; Polvat, T; Prasertporn, T; Suwanjang, W, 2023) |
| "Taken together, our study indicates that opioid addiction is associated with mtDNA copy number reduction and neurostructural remodeling." | 1.39 | Decreased mitochondrial DNA copy number in the hippocampus and peripheral blood during opiate addiction is mediated by autophagy and can be salvaged by melatonin. ( Feng, YM; Jia, YF; Lv, L; Su, LY; Wang, D; Xu, L; Yao, YG, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.86) | 18.7374 |
| 1990's | 5 (14.29) | 18.2507 |
| 2000's | 11 (31.43) | 29.6817 |
| 2010's | 14 (40.00) | 24.3611 |
| 2020's | 4 (11.43) | 2.80 |
| Authors | Studies |
|---|---|
| Osler, M | 1 |
| Jørgensen, MB | 1 |
| De, A | 1 |
| Grasing, KW | 1 |
| Polvat, T | 1 |
| Prasertporn, T | 1 |
| Na Nakorn, P | 1 |
| Pannengpetch, S | 1 |
| Suwanjang, W | 1 |
| Panmanee, J | 1 |
| Ngampramuan, S | 1 |
| Cornish, JL | 1 |
| Chetsawang, B | 1 |
| Morera-Fumero, AL | 1 |
| Fernandez-Lopez, L | 1 |
| Abreu-Gonzalez, P | 1 |
| Baandrup, L | 4 |
| Ebdrup, BH | 1 |
| Rasmussen, JØ | 1 |
| Lindschou, J | 2 |
| Gluud, C | 2 |
| Glenthøj, BY | 3 |
| Lähteenmäki, R | 2 |
| Neuvonen, PJ | 2 |
| Puustinen, J | 2 |
| Vahlberg, T | 2 |
| Partinen, M | 2 |
| Räihä, I | 2 |
| Kivelä, SL | 2 |
| Hardman, MI | 1 |
| Sprung, J | 1 |
| Weingarten, TN | 1 |
| Feng, YM | 1 |
| Jia, YF | 1 |
| Su, LY | 1 |
| Wang, D | 1 |
| Lv, L | 1 |
| Xu, L | 1 |
| Yao, YG | 1 |
| Lyles, A | 1 |
| Winkel, P | 1 |
| Glenthoj, BY | 1 |
| Garmabi, B | 1 |
| Vousooghi, N | 1 |
| Vosough, M | 1 |
| Yoonessi, A | 1 |
| Bakhtazad, A | 1 |
| Zarrindast, MR | 1 |
| Jennum, PJ | 2 |
| Fasmer, OB | 1 |
| Garzón, C | 1 |
| Guerrero, JM | 1 |
| Aramburu, O | 1 |
| Guzmán, T | 1 |
| Wei, YM | 2 |
| Xu, Y | 2 |
| Yu, CX | 2 |
| Han, J | 1 |
| Goodwin, GM | 1 |
| Emsley, R | 1 |
| Rembry, S | 1 |
| Rouillon, F | 1 |
| Owen, RT | 1 |
| Cemek, M | 2 |
| Büyükokuroğlu, ME | 2 |
| Hazman, Ö | 2 |
| Bulut, S | 2 |
| Konuk, M | 2 |
| Birdane, Y | 1 |
| Birdane, YO | 1 |
| Li, SX | 1 |
| Liu, LJ | 1 |
| Jiang, WG | 1 |
| Sun, LL | 1 |
| Zhou, SJ | 1 |
| Le Foll, B | 1 |
| Zhang, XY | 1 |
| Kosten, TR | 1 |
| Lu, L | 1 |
| van Maanen, A | 1 |
| Meijer, AM | 1 |
| Smits, MG | 1 |
| Oort, FJ | 1 |
| Xin, W | 1 |
| Chun, W | 1 |
| Ling, L | 1 |
| Wei, W | 1 |
| Bearn, J | 1 |
| Gupta, R | 1 |
| Stewart, D | 1 |
| English, J | 1 |
| Gossop, M | 1 |
| Zhou, YH | 1 |
| Huo, ZY | 1 |
| Qiu, XC | 1 |
| Peles, E | 1 |
| Hetzroni, T | 1 |
| Bar-Hamburger, R | 1 |
| Adelson, M | 1 |
| Schreiber, S | 1 |
| Lemoine, P | 1 |
| Nir, T | 1 |
| Laudon, M | 1 |
| Zisapel, N | 1 |
| Schmitz, MM | 1 |
| Sepandj, A | 1 |
| Pichler, PM | 1 |
| Rudas, S | 1 |
| Leibenluft, E | 1 |
| Feldman-Naim, S | 1 |
| Turner, EH | 1 |
| Wehr, TA | 1 |
| Rosenthal, NE | 1 |
| Giladi, N | 1 |
| Shabtai, H | 1 |
| Qiu, Y | 2 |
| Kang, L | 1 |
| Qiu, X | 2 |
| Zhdanova, IV | 1 |
| Piotrovskaya, VR | 1 |
| He, W | 1 |
| Zhu, X | 1 |
| Wang, H | 1 |
| Majumdar, SK | 1 |
| Miles, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Exploring the Utility and Safety of Benzodiazepine Prescribing Among People Receiving Opiate Replacement Therapy in Scotland (the BENZORT Study).[NCT04622995] | 46,899 participants (Actual) | Observational | 2021-08-01 | Completed | |||
| Prolonged-release Melatonin Versus Placebo for Benzodiazepine Discontinuation in Patients With Schizophrenia: a Randomized Clinical Trial[NCT01431092] | Phase 4 | 86 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| Feasibility and Efficacy of an Internet-delivered Cognitive-behavioral Intervention for Insomnia in a National Cohort of Danish Breast Cancer Survivors[NCT02444026] | 225 participants (Anticipated) | Interventional | 2014-12-31 | Recruiting | |||
| [NCT00261183] | Phase 3 | 100 participants | Interventional | 2004-12-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for melatonin and Drug Withdrawal Symptoms
| Article | Year |
|---|---|
Melatonin and melatonin agonists as treatments for benzodiazepines and hypnotics withdrawal in patients with primary insomnia. A systematic review.
Topics: Adult; Benzodiazepines; Clinical Trials as Topic; Cross-Over Studies; Double-Blind Method; Female; H | 2020 |
Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users.
Topics: Adult; Antidepressive Agents; Aspartic Acid; Benzodiazepines; Buspirone; Carbamazepine; Ethylamines; | 2018 |
Acute phenibut withdrawal: A comprehensive literature review and illustrative case report.
Topics: Akathisia, Drug-Induced; Baclofen; Cyproheptadine; Dexmedetomidine; Diphenhydramine; GABA-A Receptor | 2019 |
Agomelatine: a novel pharmacological approach to treating depression.
Topics: Acetamides; Animals; Antidepressive Agents; Anxiety; Depressive Disorder, Major; Drug Interactions; | 2009 |
11 trials available for melatonin and Drug Withdrawal Symptoms
| Article | Year |
|---|---|
Withdrawal from long-term use of zopiclone, zolpidem and temazepam may improve perceived sleep and quality of life in older adults with primary insomnia.
Topics: Aged; Aged, 80 and over; Azabicyclo Compounds; Double-Blind Method; Female; Humans; Hypnotics and Se | 2019 |
Melatonin for sedative withdrawal in older patients with primary insomnia: a randomized double-blind placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Double-Blind Method; Female; Humans; Hypnotics and Sedatives; Male; Melaton | 2014 |
Prolonged-release melatonin versus placebo for benzodiazepine discontinuation in patients with schizophrenia or bipolar disorder: A randomised, placebo-controlled, blinded trial.
Topics: Adult; Aged; Benzodiazepines; Bipolar Disorder; Denmark; Double-Blind Method; Female; Humans; Logist | 2016 |
Objective and subjective sleep quality: Melatonin versus placebo add-on treatment in patients with schizophrenia or bipolar disorder withdrawing from long-term benzodiazepine use.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Central Nervous System Depressants; | 2016 |
Circadian rest-activity rhythms during benzodiazepine tapering covered by melatonin versus placebo add-on: data derived from a randomized clinical trial.
Topics: Actigraphy; Adult; Benzodiazepines; Circadian Rhythm; Double-Blind Method; Female; Humans; Male; Mel | 2016 |
Effect of melatonin administration on sleep, behavioral disorders and hypnotic drug discontinuation in the elderly: a randomized, double-blind, placebo-controlled study.
Topics: Aged; Aged, 80 and over; Anxiety; Behavioral Symptoms; Cross-Over Studies; Depression; Double-Blind | 2009 |
Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial.
Topics: Acetamides; Adolescent; Adult; Aged; Depressive Disorder, Major; Double-Blind Method; Drug Administr | 2009 |
Termination of short term melatonin treatment in children with delayed Dim Light Melatonin Onset: effects on sleep, health, behavior problems, and parenting stress.
Topics: Central Nervous System Depressants; Child; Child Behavior; Child, Preschool; Drug Administration Sch | 2011 |
Melatonin for perceived sleep disturbances associated with benzodiazepine withdrawal among patients in methadone maintenance treatment: a double-blind randomized clinical trial.
Topics: Analgesics, Opioid; Anti-Anxiety Agents; Benzodiazepines; Central Nervous System Depressants; Circad | 2007 |
Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects.
Topics: Aged; Arousal; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Male; Melatonin; Mi | 2007 |
Effects of exogenous melatonin administration and withdrawal in five patients with rapid-cycling bipolar disorder.
Topics: Affect; Bipolar Disorder; Circadian Rhythm; Double-Blind Method; Drug Administration Schedule; Drug | 1997 |
20 other studies available for melatonin and Drug Withdrawal Symptoms
| Article | Year |
|---|---|
Association of benzodiazepines, Z-drugs, pregabalin, and melatonin with traffic accidents: A nationwide cohort and case-crossover study in Danish adults.
Topics: Accidents, Traffic; Adolescent; Adult; Aged; Alcoholism; Benzodiazepines; Chlordiazepoxide; Cohort S | 2022 |
The antidepressant agomelatine attenuates morphine-induced reinstatement but not self-administration or precipitated withdrawal.
Topics: Analgesics, Opioid; Animals; Antidepressive Agents; Male; Melatonin; Morphine; Naloxone; Narcotic An | 2023 |
Proteomic Analysis Reveals the Neurotoxic Effects of Chronic Methamphetamine Self-Administration-Induced Cognitive Impairments and the Role of Melatonin-Enhanced Restorative Process during Methamphetamine Withdrawal.
Topics: Animals; Cognitive Dysfunction; Humans; Melatonin; Methamphetamine; Mice; Proteomics; Substance With | 2023 |
Decreased mitochondrial DNA copy number in the hippocampus and peripheral blood during opiate addiction is mediated by autophagy and can be salvaged by melatonin.
Topics: Analgesics; Animals; Autophagy; Behavior, Animal; Cells, Cultured; Dendrites; DNA, Mitochondrial; Ge | 2013 |
Effect of circadian rhythm disturbance on morphine preference and addiction in male rats: Involvement of period genes and dopamine D1 receptor.
Topics: Animals; Circadian Rhythm; Corpus Striatum; Disease Models, Animal; Male; Melatonin; Morphine; Morph | 2016 |
Melatonin enhances the expression of β-endorphin in hypothalamic arcuate nucleus of morphine-dependent mice.
Topics: Animals; Arcuate Nucleus of Hypothalamus; beta-Endorphin; Male; Melatonin; Mice; Morphine; Morphine | 2009 |
Sleep complaints: Whenever possible, avoid the use of sleeping pills.
Topics: Acupuncture Therapy; Adult; Aged; Behavior Therapy; Benzodiazepines; Clinical Trials as Topic; Conge | 2008 |
Antioxidant enzyme and element status in heroin addiction or heroin withdrawal in rats: effect of melatonin and vitamin E plus Se.
Topics: Animals; Antioxidants; Heroin Dependence; Male; Melatonin; Rats; Rats, Sprague-Dawley; Selenium; Sub | 2011 |
The roles of melatonin and vitamin E plus selenium in prevention of oxidative stress induced by naloxone-precipitated withdrawal in heroin-addicted rats.
Topics: Animals; Antioxidants; Ceruloplasmin; Glutathione; Heroin; Heroin Dependence; Lipid Peroxidation; Ma | 2011 |
Circadian alteration in neurobiology during protracted opiate withdrawal in rats.
Topics: Adrenocorticotropic Hormone; Animals; Behavior, Animal; beta-Endorphin; Brain; Circadian Rhythm; Dis | 2010 |
Role of melatonin in the prevention of morphine-induced hyperalgesia and spinal glial activation in rats: protein kinase C pathway involved.
Topics: Analgesics; Animals; Disease Models, Animal; Hyperalgesia; Male; Melatonin; Morphine Dependence; Pai | 2012 |
Sulphatoxymelatonin excretion during opiate withdrawal: a preliminary study.
Topics: Adult; Female; Humans; Male; Melatonin; Opioid-Related Disorders; Substance Withdrawal Syndrome | 2002 |
[Inhibitory effect of melatonin on morphine withdrawal syndromes and the content of NO in plasma and brain tissue in morphine dependent mice].
Topics: Animals; Brain; Disease Models, Animal; Male; Melatonin; Mice; Morphine Dependence; Nitric Oxide; Su | 2002 |
[Effect of melatonin on the content of β-endorphin in the hypothalamic arcuate nucleus and periaqueductal grey of midbrain in morphine withdrawal mice].
Topics: Animals; Arcuate Nucleus of Hypothalamus; beta-Endorphin; Male; Melatonin; Mesencephalon; Mice; Morp | 2007 |
Disrupted melatonin-secretion during alcohol withdrawal.
Topics: Adult; Alcoholism; Biological Clocks; Female; Humans; Male; Melatonin; Middle Aged; Substance Withdr | 1996 |
Melatonin-induced withdrawal emergent dyskinesia and akathisia.
Topics: Adult; Akathisia, Drug-Induced; Dyskinesia, Drug-Induced; Female; Humans; Hypnotics and Sedatives; M | 1999 |
[The inhibitory effect of melatonin on morphine withdrawal syndromes and serum monoamines in morphine dependent mice].
Topics: Animals; Dopamine; Male; Melatonin; Mice; Morphine; Morphine Dependence; Norepinephrine; Substance W | 1998 |
Melatonin treatment attenuates symptoms of acute nicotine withdrawal in humans.
Topics: Adult; Female; Humans; Male; Melatonin; Middle Aged; Nicotine; Psychomotor Performance; Saliva; Smok | 2000 |
[Effect of melatonin on mean blood pressure and heart rate in morphine withdrawal rats].
Topics: Animals; Antihypertensive Agents; Blood Pressure; Heart Rate; Hypertension; Male; Melatonin; Morphin | 1998 |
Disturbed melatonin secretion in chronic alcoholism and withdrawal.
Topics: Adult; Alcoholism; Ethanol; Humans; Male; Melatonin; Middle Aged; Substance Withdrawal Syndrome | 1987 |